Company
Becton Dickinson (BD)
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
260
510(k), De Novo and PMA
Device trials
44
As lead sponsor, any status
Adverse event reports
39,229
Received Nov 1, 2025 to Nov 20, 2026
Recall records
1,047
One per recalled product
Becton Dickinson (BD) is on our public-company list (ticker BDX). Names searched as well: Becton Dickinson, Becton, Dickinson, C.R. Bard, Bard Peripheral Vascular. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
BDX
NYSE · BECTON DICKINSON & CO
Public float
Unknown
Not reported in US filings
Revenue
$21.8B
Fiscal year ending Sep 30, 2025
Net income
$1.68B
Fiscal year ending Sep 30, 2025
R&D spending
$1.26B
Fiscal year ending Sep 30, 2025
Cash
$708M
As of Jun 30, 2026
Long-term debt
$13.5B
As of Jun 30, 2026
Shares outstanding
272.4M
As of Jun 30, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2024 | – | – | $4.52B | – |
| 2023 | – | – | $1.66B | – |
| 2022 | – | – | $497M | – |
| 2021 | – | – | $4.87B | – |
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
The 8 newest of 260 since 2015.
K261379 · Decided Oct 27, 2026 · 183 days after receipt
Device type: Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings (QVF) · Laboratory Medicine & Pathology
K252344 · Decided Oct 16, 2026 · 445 days after receipt
Device type: Tubes, Vials, Systems, Serum Separators, Blood Collection (JKA) · Laboratory Medicine & Pathology
K261543 · Decided Sep 28, 2026 · 143 days after receipt
Device type: Mesh, Surgical, Absorbable, Abdominal Hernia (OWT) · General & Plastic Surgery
257 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Evaluation of Catheter Utilization in Female Patients Using Indwelling Urinary Catheters and the PureWick™ Flex Female External CatheterNot yet recruiting
NCT07798128 · 240 participants (planned) · Start Nov 6, 2026 · Primary completion Jun 30, 2027
Device: PureWick™ Flex Female External Catheter (FFEC); Indwelling Urinary Catheter (IUC) · For: Urinary Incontinence; Limited Mobility
- HemoSphere Alta StudyRecruiting
NCT07148323 · 100 participants (planned) · Start Oct 14, 2025 · Primary completion Nov 2026
Device: HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor · For: Hemodynamic Instability
Sites: Rochester, New York
- Personal BP - CAI StudyRecruiting
NCT06492746 · 120 participants (planned) · Start Jun 3, 2024 · Primary completion Jan 2027
Device: HemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry Monitoring · For: Blood Pressure
Sites: Evanston, Illinois
41 more trials with a free account
Reports received
39,229
Received Nov 1, 2025 to Nov 20, 2026. Includes 26 of another or unstated type.
Malfunction reports
32,637
83% of reports
Injury reports
6,306
16% of reports
Death reports
260
0.7% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 2,294 | 572 | 4 | 1 |
| Jan 24 | 1,992 | 606 | 7 | 1 |
| Feb 24 | 2,104 | 778 | 7 | 0 |
| Mar 24 | 2,110 | 910 | 3 | 1 |
| Apr 24 | 2,134 | 825 | 7 | 3 |
| May 24 | 2,321 | 1,041 | 10 | 1 |
| Jun 24 | 2,248 | 472 | 2 | 1 |
| Jul 24 | 2,356 | 943 | 9 | 1 |
| Aug 24 | 2,364 | 790 | 6 | 1 |
| Sep 24 | 2,134 | 397 | 10 | 0 |
| Oct 24 | 2,337 | 263 | 5 | 2 |
| Nov 24 | 2,477 | 313 | 2 | 4 |
| Dec 24 | 2,991 | 340 | 2 | 1 |
| Jan 25 | 2,420 | 370 | 7 | 0 |
| Feb 25 | 2,771 | 371 | 8 | 0 |
| Mar 25 | 2,751 | 414 | 14 | 0 |
| Apr 25 | 3,109 | 348 | 9 | 1 |
| May 25 | 2,704 | 429 | 2 | 0 |
| Jun 25 | 3,126 | 502 | 4 | 1 |
| Jul 25 | 4,411 | 688 | 6 | 2 |
| Aug 25 | 5,469 | 502 | 10 | 3 |
| Sep 25 | 6,474 | 654 | 14 | 1 |
| Oct 25 | 2,951 | 620 | 17 | 0 |
| Nov 25 | 3,492 | 536 | 24 | 0 |
| Dec 25 | 2,855 | 591 | 25 | 4 |
| Jan 26 | 2,388 | 375 | 19 | 0 |
| Feb 26 | 2,816 | 519 | 13 | 0 |
| Mar 26 | 2,626 | 574 | 29 | 0 |
| Apr 26 | 2,739 | 535 | 16 | 3 |
| May 26 | 2,315 | 448 | 19 | 1 |
| Jun 26 | 2,414 | 590 | 29 | 0 |
| Jul 26 | 2,744 | 482 | 12 | 3 |
| Aug 26 | 2,480 | 645 | 32 | 15 |
| Sep 26 | 2,969 | 451 | 27 | 0 |
| Oct 26 | 2,799 | 560 | 15 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
7 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
- MAXCORE2,531
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- EnCor EnCompass Breast Biopsy and Tissue Removal System Console (model number: ENCPCONSOLE) and Driver (model number: ENCPDRIVER) with softwareOpen, Classified
Z-3275-2026 · Started Aug 20, 2026 · Posted by FDA Sep 25, 2026
Reason given: Breast biopsy and tissue removal system may experience the following errors: 1) Probe calibration and /or handheld driver failure (code HH01-00020009) , 2) Pressure sensor (code E01-0054000E), which prompts the user to restart and re-calibrate; errors may lead to interruption or prolongation of the biopsy procedure,...
Cause as FDA categorized it: Software design · Device type: Instrument, Biopsy (KNW)
- BD Phoenix Panel NMIC-312. Catalog Number: 449082.Open, Classified
Z-0139-2027 · Started Aug 13, 2026 · Posted by FDA Oct 9, 2026
Reason given: Potential for quality control failures with Klebsiella pneumoniae ATCC BAA-1705 when using the CPO Ambler classification feature.
Cause as FDA categorized it: Under Investigation by firm · Device type: System, Test, Automated, Antimicrobial Susceptibility, Short Incubation (LON)
- BD Phoenix Panel NMIC-306. Catalog Number: 449292.Open, Classified
Z-0140-2027 · Started Aug 13, 2026 · Posted by FDA Oct 9, 2026
Reason given: Potential for quality control failures with Klebsiella pneumoniae ATCC BAA-1705 when using the CPO Ambler classification feature.
Cause as FDA categorized it: Under Investigation by firm · Device type: System, Test, Automated, Antimicrobial Susceptibility, Short Incubation (LON)
1,044 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.